antibiotics Article Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study Daniele Roberto Giacobbe 1,2,*, Chiara Russo 1,2, Veronica Martini 3, Silvia Dettori 1,2, Federica Briano 1,2, Michele Mirabella 2, Federica Portunato 2, Chiara Dentone 2, Sara Mora 4, Mauro Giacomini 4 , Marco Berruti 1,2 and Matteo Bassetti 1,2 1 Department of Health Sciences, University of Genoa, 16132 Genoa, Italy;
[email protected] (C.R.);
[email protected] (S.D.);
[email protected] (F.B.);
[email protected] (M.B.);
[email protected] (M.B.) 2 Clinica Malattie Infettive, San Martino Policlinico Hospital—IRCCS, 16132 Genoa, Italy;
[email protected] (M.M.);
[email protected] (F.P.);
[email protected] (C.D.) 3 School of Medicine, University of Genoa, 16132 Genoa, Italy;
[email protected] 4 Department of Informatics Bioengineering, Robotics, and Systems Engineering (DIBRIS), University of Genoa, 16145 Genoa, Italy;
[email protected] (S.M.);
[email protected] (M.G.) * Correspondence:
[email protected] Abstract: A single-center cross-sectional study was conducted to describe the use of ceftaroline in a large teaching hospital in Northern Italy, during a period also including the first months of the coronavirus disease 2019 (COVID-19) pandemic. The primary objective was to describe the use of ceftaroline in terms of indications and characteristics of patients. A secondary objective was to Citation: Giacobbe, D.R.; Russo, C.; describe the rate of favorable clinical response in patients with bloodstream infections (BSI) due to Martini, V.; Dettori, S.; Briano, F.; methicillin-resistant Staphylococcus aureus (MRSA-BSI) receiving ceftaroline.